Moderna, Inc. (MRNA) – Falling sales and increasing cost shows concern

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Moderna, Inc. (MRNA) (Q4FY22)

Highlights

MRNA revenue increased by $792mn, or 4%, in 2022, primarily due to an increase in product sales. Product sales increased by $760mn, or 4%, in 2022 from sales of COVID-19 vaccines to domestic and international government customers and organizations, largely attributable to a higher average selling price and customer mix.

Moderna is exploring its mRNA technology for development of other vaccines. Interest in mRNA therapy has exploded in recent years following the development of mRNA-based COVID-19 vaccines.

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages : 33

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates